Aurobindo Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

The transaction, valued at $250 million on a cash-free, debt-free basis, including normalized working capital, is expected to be completed before the end of June 2026.

Lannett, a Pennsylvania-based generic pharmaceutical company, focuses on the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition is expected to significantly strengthen Aurobindo USA?s presence in this segment while adding a U.S.-based manufacturing facility to its operations.

The deal includes Lannett?s manufacturing facility in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA?s domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.

According to the company, the acquisition is expected to be immediately accretive to the Aurobindo Group?s earnings per share. It is also anticipated to generate cost efficiencies, SG&A synergies and operational integration benefits while expanding the company?s portfolio of complex generics and controlled substances, supporting long-term growth.

Swami S. Iyer, chief executive officer of Aurobindo Pharma USA, said, ?This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances. We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion. We are pleased to welcome the Lannett team and look forward to leveraging our combined strengths to expand and ensure reliable access to critical medications for patients.?

Tim Crew, Lannett Company?s chief executive officer, said, ?We are delighted to be joining forces with Aurobindo. As one of the nation?s oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. Aurobindo?s market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere. Our board and owners extend their sincere appreciation to the outstanding teams at both companies whose professionalism, commitment, and hard work have successfully brought us to this important moment. We look forward to building on all that has come before as we begin a bright and exciting next chapter.?

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.

The counter shed 0.92% to Rs 1,484 on the BSE.

Powered by Capital Market - Live News

Aurobindo Pharma USA, Inc. (Aurobindo USA), a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (Lannett).

The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026.

Lannett, a Pennsylvania-based generic pharmaceutical company, specializes in the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances.

The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a U.S.-based manufacturing facility to its network.

Lannett's manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA's domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.

The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share. In addition to near-term financial benefits, the acquisition is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. It will also enhance the company's portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.

Aurobindo Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1479.9, up 2.51% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.88% on the day, quoting at 23954.5. The Sensex is at 76644.39, down 0.99%. Aurobindo Pharma Ltd has slipped around 2.48% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 1.61% in last one month and is currently quoting at 24282.2, up 0.66% on the day. The volume in the stock stood at 11.78 lakh shares today, compared to the daily average of 13.39 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1483.2, up 2.49% on the day. Aurobindo Pharma Ltd is up 34.88% in last one year as compared to a 4.61% drop in NIFTY and a 13.09% drop in the Nifty Pharma index.

The PE of the stock is 34.51 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Aurobindo Pharma announced that its wholly owned subsidiary, Aurobindo Pharma USA Inc. has received the approval from US Federal Trade Commission (FTC) for the acquisition of 100% of membership interest in Lannett Company LLC from LANNETT SELLER HOLDCO, INC.